K Number
K183332
Device Name
“BRAXX” Esophageal Brachytherapy Applicator
Date Cleared
2019-04-16

(134 days)

Product Code
Regulation Number
892.5700
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Esophageal Brachytherapy Applicator is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery of radioactive source to the esophagus. This device is sterile, disposable and single-use. For prescription use only
Device Description
A main catheter with inflatable balloons
More Information

No
The summary describes a mechanical device for delivering radiation and does not mention any AI/ML components or image processing.

Yes
The device is used for the delivery of radioactive sources for brachytherapy, which is a therapeutic intervention for medical conditions.

No
Explanation: The device is an applicator for delivering a radioactive source during brachytherapy, which is a treatment, not a diagnostic procedure. Its purpose is for delivery, not detection, diagnosis, or monitoring of a disease.

No

The device description clearly states it is a "main catheter with inflatable balloons," indicating a physical hardware component. The performance studies also mention "Mechanical testing," further confirming it is not software-only.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
  • Device Function: The description clearly states the device is an "Esophageal Brachytherapy Applicator" intended for "delivery of radioactive source to the esophagus." This is a therapeutic device used for delivering radiation directly to a tumor or affected area within the body, not for testing samples outside the body.
  • Intended Use: The intended use is for brachytherapy, a form of radiation therapy, not for diagnostic testing of biological samples.

Therefore, this device falls under the category of a therapeutic medical device, not an in vitro diagnostic device.

N/A

Intended Use / Indications for Use

The Esophageal Brachytherapy Applicator is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery of radioactive source to the esophagus. This device is sterile, disposable and single-use.

Product codes

JAQ

Device Description

A main catheter with inflatable balloons

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Esophagus

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Target User Population: Radiation oncologists
Where Used: Hospital O.R. room

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Performance testing has been carried out to demonstrate that this device meets the performance specifications for its intend use. The following tests were performed on the device.
Biocompatibility testing: The biocompatibility evaluation and testing of the Esophageal Brachytherapy Applicator was conducted in accordance with the following standards and guidance, as recognized by the FDA: FDA Draft Guidance Use of International Standard ISO- 10993, "Biological Evaluation O of Medical Devices, Part 1: Evaluation and Testing", dated 04-23-2013, ISO 10993-5, Biological evaluation of medical devices- Part 5: Tests for in vitro cytotoxicity, 10993-10, Biological evaluation of medical devices- Part 10: Tests for irritation and skin 0 sensitization, ISO 10993-11, Biological evaluation of medical devices- Part 11: Tests for systemic toxicity, USP 151, Pyrogen Test in White Rabbits.
Sterilization Validation: Sterilization validation was conducted in accordance with ISO 11135:2014 "Sterilization of health-care products -- Ethylene oxide -- Requirements for the development, validation and routine control of a sterilization process for medical devices". Sterilization has been validated to achieve a Sterility Assurance Level (SAL) of 10-6.
Mechanical testing: Esophageal Brachytherapy Applicator's mechanical function and structure integrity were tested and demonstrated that the design specification from design input are fulfilled and that the device raises no safety concern.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K142719, K162499

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 892.5700 Remote controlled radionuclide applicator system.

(a)
Identification. A remote controlled radionuclide applicator system is an electromechanical or pneumatic device intended to enable an operator to apply, by remote control, a radionuclide source into the body or to the surface of the body for radiation therapy. This generic type of device may include patient and equipment supports, component parts, treatment planning computer programs, and accessories.(b)
Classification. Class II.

0

Section 4 Indications for Use Statement

FORM FDA 3881

1

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below.

510(k) Number (if known)

K183332

Device Name Esophageal Brachytherapy Applicator

Indications for Use (Describe)

The Esophageal Brachytherapy Applicator is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery of radioactive source to the esophagus. This device is sterile, disposable and single-use.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

FORM FDA 3881 (7/17)

Page 1 of 1

PSC Publishing Services (301) 443-6740 EF

2

Section 5 510(k) Summary

510(k) Summary of Safety and Effectiveness

This 510(k) summary of safety and effectiveness information is submitted as part of the Premarket Notification in compliance with requirements of CFR Part 807, Subpart E and Section 807.92

The assigned 510(k) Number: K183332

  • Submitter 1.

| Mailing Address | BRAXX Biotech Co. Ltd
6F., No.10, Songde Rd., Xinyi Dist
Taipei City, 11076, Taiwan R.O.C
Establishment Registration No.: NA (1st submission) |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person | Judy Kao |
| Phone: | 886-921988206 |
| E-mail: | judy.kao@braxx.com.tw |
| Date Prepared | 2018/11/27 |

2 Device Name

Proprietary Name Common name Product Code Device CFR Classification Device Class Classification Panel

"BRAXX" Esophageal Brachytherapy Applicator Esophageal Brachytherapy Applicator JAQ System, Applicator, Radionuclide, Remote-Controlled 21 CFR 892.5700 II Remote controlled radionuclide applicator system

3 Predicate Device Name

510(k) number: Trade or proprietary name: Manufacturer:

510(k) number: Trade or proprietary name: Manufacturer:

5. Intended Use:

K142719 E-App (Esophageal Applicator) BIONIX RADIATION THERAPY, LLC

K162499

Intraluminal Balloon Applicator for Brachytherapy Best Medical International, Inc

The Esophageal Brachytherapy Applicator is intended for use with commercially available afterloader during brachytherapy. The purpose of the device is for delivery

3

Image /page/3/Picture/0 description: The image shows the logo for BRAXX. The logo consists of the word "BRAXX" in a bold, sans-serif font, with a stylized "B" that incorporates a small orange circle. Below the word "BRAXX" are three Chinese characters.

of radioactive source to the esophagus. This device is sterile, disposable and single-use. For prescription use only

Special Conditions for Use Statement(s):

Characteristics and

Substantial Equivalence

Comparison with Predicate:

Technological

A comparison of the device features, intended use, and other information demonstrates that the Esophageal Brachytherapy Applicator is substantially equivalent to the predicate device as summarized in Table 1.

| Device name | Subject device:
Esophageal
Brachytherapy
Applicator | Predicate device:
E-App | Predicate device:
Best® Intraluminal
Balloon Applicator for
Brachytherapy |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use | The Esophageal
Brachytherapy Applicator
is intended for use with
commercially available
afterloader during
brachytherapy. The
purpose of the device is for
delivery of radioactive
source to the esophagus.
This device is sterile,
disposable and single-use. | The GC Medtech
Esophageal
applicator(E-App) is an
applicator used to facilitate
delivery of a prescription of
radiation to the esophagus
when used in conjunction
with a high dose rate
after-loader. | Best® Intraluminal
Balloon Applicator for
Brachytherapy is intended
to provide brachytherapy
when the physician
chooses to deliver radiation
to an existing body site
such as the esophagus or
bronchus. It is supplied as a
single-use sterile device.
The device is indicated for
use under the direct
supervision of a qualified
physician. |
| Target patient
Population | Esophageal cancer patients | Same | Same |
| Target User
Population | Radiation oncologists | Same | Same |
| Anatomical
Site | Esophagus | Same | Same |
| Where Used | Hospital O.R. room | Same | Same |
| Design | A main catheter with
inflatable balloons | Same | Same |
| Performance | For centering the treatment
catheter (radioactive
source) within the lumen
by inflated balloons. | Same | Same |
| Biocompatible | Fully biocompatible | Same | Same |
| Sterilization
Method | Ethylene Oxide | Same | Same |
| Single Use | Single use | Same | Same |

Table 1

4

7. Performance Testing

Performance testing has been carried out to demonstrate that this device meets the performance specifications for its intend use. The following tests were performed on the device.

Biocompatibility testing

The biocompatibility evaluation and testing of the Esophageal Brachytherapy Applicator was conducted in accordance with the following standards and guidance, as recognized by the FDA:

  • FDA Draft Guidance Use of International Standard ISO- 10993, "Biological Evaluation O of Medical Devices, Part 1: Evaluation and Testing", dated 04-23-2013
  • 0 ISO 10993-5, Biological evaluation of medical devices- Part 5: Tests for in vitro cytotoxicity
  • 10993-10, Biological evaluation of medical devices- Part 10: Tests for irritation and skin 0 sensitization
  • 0 ISO 10993-11, Biological evaluation of medical devices- Part 11: Tests for systemic toxicity.
  • O USP 151, Pyrogen Test in White Rabbits

Sterilization Validation

Sterilization validation was conducted in accordance with ISO 11135:2014 "Sterilization of health-care products -- Ethylene oxide -- Requirements for the development, validation and routine control of a sterilization process for medical devices". Sterilization has been validated to achieve a Sterility Assurance Level (SAL) of 10-6.

Mechanical testing

Esophageal Brachytherapy Applicator's mechanical function and structure integrity were tested and demonstrated that the design specification from design input are fulfilled and that the device raises no safety concern.

8. Conclusion

Based on the intended use and/or indications for use, technological characteristics, performance testing and comparison to the predicate device, the Esophageal Brachytherapy Applicator is substantially equivalent to the predicate device and raises no new questions of safety or effectiveness.

5

BRAXX Biotech Co., Ltd. % Ms. Judy Kao Regulatory Affairs Representative 6F., No.10, Songde Rd., Xinyi Dist Taipei City, 11076 Taiwan REPUBLIC OF CHINA

April 16, 2019

Re: K183332

Trade/Device Name: "BRAXX" Esophageal Brachytherapy Applicator Regulation Number: 21 CFR 892.5700 Regulation Name: Remote controlled radionuclide applicator system Regulatory Class: Class II Product Code: JAQ Dated: February 27, 2019 Received: March 8, 2019

Dear Ms. Kao:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809; medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see

6

https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

For

Thalia T. Mills, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure